Hepatoblastoma
Jump to navigation
Jump to search
| Section editor | |
|---|---|
 |
Wayne H. Liang, MD, MS Birmingham, AL Twitter: WayneLiangMD |
7 regimens on this page
7 variants on this page
|
All lines of therapy
Cisplatin monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Perilongo et al. 2009 (SIOPEL 3) | Phase III (E) | Cisplatin & Doxorubicin | Non-inferior complete resection rate |
Chemotherapy
References
- SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed
Cisplatin & Doxorubicin
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Perilongo et al. 2009 (SIOPEL 3) | Phase III (C) | Cisplatin | Non-inferior complete resection rate |
Chemotherapy
References
- SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed